Company
Why Takeda Pharmaceutical Co ADR (NYSE: TAK) Stock Shouldn’t Be Sold In 2025
In the latest trading session,, 1.22 million Takeda Pharmaceutical Co ADR (NYSE:TAK) shares changed hands as the company’s beta touched 0.26. With the company’s most